CSTL — Castle Biosciences, Inc.
$33.79
$-0.71 (-2.06%)
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Market Cap
$1.04B
Forward P/E
-52.3x
52-Week Range
N/A
CSTL Price History
Revenue vs. Net Income
$344M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$28.3M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-5.8%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
5.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
10.5%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-0.9%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
